...WHO Group 3) to improve exercise ability. It was first approved in 2009 to treat PAH...

...said FDA’s latest action confers full approval on Lorbrena.End of the road for United Therapeutics’ PAH...

...and Eisai also have the product in Phase II testing to treat pulmonary arterial hypertension (PAH).D...

...inhaler —to treat pulmonary arterial hypertension (PAH...

...PKR activation has applications in more than 20 indications. Agios also has preclinical programs targeting PAH...

...and interventional radiology at Stanford University and was CMO at Graybug Vision Inc. (NASDAQ:GRAY).Setback for Liquidia PAH...

...pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH...

...initiated a collaboration with Chiesi Farmaceutici S.p.A. to develop mRNA therapies for pulmonary arterial hypertension (PAH).From...

...A round to support clinical testing of an inhaled dry powder formulation of imatinib for PAH...
...the core issue of proliferation. When Novartis AG (NYSE:NVS; SIX:NOVN) took cancer drug Gleevec imatinib through Phase III testing in PAH...
...found that the antiproliferative tyrosine kinase inhibitor significantly improved 6-minute walk (6MW) distance, the standard primary endpoint in PAH...

...lung delivery platform in additional pulmonary diseases, including primary ciliary dyskinesia (PDC), pulmonary arterial hypertension (PAH...